| Document |
Document Title |
|
WO/2004/066963A2 |
A class of N-cyclohexylaminocarbonyl benzenesulfonamide derivatives are agonists or partial agonists or antagonists of PPAR gamma and are useful in the treatment and control of hyperglycemia that is symptomatic of type II diabetes, as we...
|
|
WO/2004/066943A2 |
Encephalotoxin produced by activated mononuclear phagocytes is present in individuals having neurological disease including neurodegenerative and neuro-inflammatory diseases, such as Alzheimer's disease (AD), HIV-1-associated dementia (H...
|
|
WO/2004/065357A1 |
A 4-hydroxy-4’-methyldiphenylsulfone material represented by the following formula (1): (1), characterized in that it exhibits, in the powder X-ray diffractometry using a Cu-K&agr line, a peak intensity at a diffraction angle (2Ѳ ± 0...
|
|
WO/2004/063148A1 |
The present invention relates to a compound of the formula ((I): in which: n is an integer chosen from 1, 2 and 3; Y represents O; N-OR9, in which R9 represents H or a saturated hydrocarbon-based aliphatic group; CR10R11, in which R10 an...
|
|
WO/2004/063149A1 |
Method for preparing methyl 2-diphenylmethylsulfinylacetate (MDMSA) comprising the steps of :(i) conversion of benzhydrol into methyldiphenylmethylthio-acetate ; and (ii) conversion of methyldiphenylmethylthioacetate into methyl-2-diphen...
|
|
WO/2004/062601A2 |
Antibacterial compounds of formula (I) are provided: As well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infectio...
|
|
WO/2004/060858A1 |
The invention relates to a method for the production of crystalline forms of optical enantiomers of modafinil, comprising the following steps:i) one of the optical enantiomers of modafinil is dissolved in a solvent other than ethanol; ii...
|
|
WO/2004/058747A1 |
The present invention provides compounds capable of binding to an Fc receptor and modulating Fc receptor activity comprising a core lipophilic group in the form of an Aryl ring substituted with a group rich in p-electrons. The invention ...
|
|
WO/2004/058698A1 |
The invention relates to a method for oxidizing optionally substituted toluols of the formula (I), wherein X, Y and Z independently represent hydrogen, methylsulfonyl, hydroxysulfonyl, nitro, halogen or optionally substituted phenyl, to ...
|
|
WO/2004/056365A2 |
A compound of formula (I): wherein R1, R2, R3 and Y are as defined herein, or a pharmaceutically-acceptable and -cleavable ester, or acid addition salt thereof, useful for promoting the release of parathyroid hormone, e.g. for preventing...
|
|
WO/2004/052830A1 |
ABSTRACT The compounds of formula (I): where Ar is an aromatic ring and Ra, Rb, are as defined in the description, are useful in therapy as drugs for the treatment of diseases mediated by infiltrations of neutrophils induced by IL-8, suc...
|
|
WO/2004/052846A1 |
This invention relates to tetrahydro-naphthalene derivatives and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The tetrahydro-naphthalene derivatives of the present invention have an excellent acti...
|
|
WO/2004/052847A2 |
The present invention relates to methods of treating pathological disorders susceptible to steroid hormone nuclear receptor modulation comprising administering to a patient in need thereof an effective amount of a compound of the formula...
|
|
WO/2004/050611A1 |
It is intended to provide a novel intermediate for producing a 5-hydroxyamidino-2-hydroxybenzenesulfonamide derivative which is useful as an activated blood coagulation factor X inhibitor, a method of producing this intermediate and a me...
|
|
WO/2004/048321A1 |
The invention relates to phenylsulfoxide and phenylsulfone derivatives and to a method for producing them. The invention also relates to their use in the production of medicaments for the treatment and/or prophylaxis of diseases, especia...
|
|
WO/2004/048309A1 |
The present invention relates to novel, non-secosteroidal, diaryl compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1a,25 dihydroxy vitamin D3. These compounds are useful for treating bone disea...
|
|
WO/2004/047772A2 |
The invention provides small molecules that act as catalytic antioxidants and methods of use thereof. The compounds can repeatedly bind and destroy reactive oxygen species by serving as substates for enzymes of the methionine sulfoxide r...
|
|
WO/2004/048322A1 |
A compound of the formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein:R1, R2, L1, L2, M1, M2, n, p, q, A, D, X, Y and Z are as described in the specification; pharmaceutical compositions thereof, methods of maki...
|
|
WO/2004/048318A1 |
An improved process for the preparation of 1,3 substituted indenes which are useful intermediates in the synthesis of aryl fused azapolycyclic compounds as agents for the treatment of neurological and psychological disorders.
|
|
WO/2004/045610A1 |
The present invention relates to a compound formula [I] or a salt thereof. The compound [I] of the present invention and pharmaceutically acceptable salts thereof are useful for the prophylactic and/or the therapeutic treatment of pollak...
|
|
WO/2004/041266A1 |
A GPR40 receptor function controlling agent which contains a compound having an aromatic ring and a group capable of releasing a cation and is useful as a insulin secretion promoting agent or a preventive/remedy for diabetes, etc.
|
|
WO/2004/039769A1 |
N-(4-Cyano-3-trifluoromethylphenyl)-3-(4fluorophenylsulfon
yl)-2-hydroxy-2-methylpropanamide of high purity is produced by oxidation of N-(4-cyano-3trifluoromethylphenyl)-3-(4-fluorophenylthio)-
2-hydroxy-2methylpropanamide, using ...
|
|
WO/2004/039770A1 |
A recording material excellent in background storage stability, especially the heat resistance and moist-heat resistance of background. The recording material contains a color-forming dye and is characterized by containing at least one d...
|
|
WO/2004/037773A1 |
The present invention relates to novel compounds of formula (I), to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of...
|
|
WO2000061134A9 |
Compounds of formula (I) are antibacterial agents wherein: Z represents a radical of formula -N(OH)CH(=O) of formula -C(=O)NH(OH) and R1-R4 are as defined in the specification.
|
|
WO/2004/033419A1 |
Compounds having methionine aminopeptidase-2 inhibitory (MetAP2) are described. Also described are pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, methods of inhibiting angiogenesis, and me...
|
|
WO/2004/031136A1 |
Bicalutamide and/or its intermediates are made by the use of pfluorobenzenesulfinic acid salt as a reagent.
|
|
WO/2004/031139A1 |
Compounds of formula (I) inhibit the processing of APP by gamma-secretase, and hence are useful in treating or preventing Alzheimer's disease.
|
|
WO/2004/031287A1 |
Compounds of the formula (I) wherein R1 is C1-C18alkyl, C5-C12-cycloalkyl, phenyl, benzyl, or allyl; n is 1 or 2; if n is 1, R2 is C4-C18alkyl, C5-C12cycloalkyl, aryl or heteroaryl, benzyl, allyl, (CH2),mCOOR3, or is (CH2)mCN; if n is ...
|
|
WO/2004/031137A1 |
Compounds of formula (I) inhibit the processing of APP by gamma-secretase, and hence are useful in treatment of Alzheimer's disease.
|
|
WO/2004/031138A1 |
The invention provides compounds of formula (I) : which are inhibitors of &gammad -secretase and hence useful in the treatment or prevention of Alzheimer's disease.
|
|
WO/2004/029020A1 |
A process for producing 4,4'-dihydroxydiphenyl sulfone having an extremely high purity. The process for producing high-purity 4,4'-dihydroxydiphenyl sulfone comprises subjecting phenol and either a sulfonating agent or phenolsulfonic aci...
|
|
WO/2004/029021A1 |
A new crystalline form of bicalutamide (form II) is disclosed. Bicalutamide form II is useful as a pharmaceutical and has antiandrogenic activity.
|
|
WO/2004/026817A1 |
An amino alcohol derivative represented by the general formula (1): (1) &lcub e.g., (±)-2-amino-5-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-
methylpentan-1-ol&rcub . It has excellent immunosuppressive activity and is reduced in side ...
|
|
WO/2004/026815A2 |
The present invention is related to a compound of the formula (I), (II), (III), (IV), (V): wherein Z1, Z2, Z3 and Z4 are each and independently selected from the group comprising C(O)-, -C(S)-, -C(O)-NR10-, -C(S)-NR11-, -C(N-CN)-NR12-, -...
|
|
WO/2004/024678A1 |
The invention disclosed certain unsaturated sulfur containing-oxime ether compounds of formula (I) with fungicidal activity, formula (I) wherein A= H, halo, CN, alkyl, alkoxy, haloalkyl, haloalkoxy; X=CH or N; Y is O, S, NR6; R1, R6 =H o...
|
|
WO/2004/024679A1 |
This invention discloses amino acid derivatives which display inhibitory effects on the serine protease factor Xa. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions ...
|
|
WO/2004/022526A1 |
This invention relates to class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resor...
|
|
WO/2004/022523A2 |
The present invention relates to compounds of formula (AA), (I) and (X), useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment ...
|
|
WO/2004/018415A1 |
Sulfonamide derivatives represented by the general formula (1) or salts thereof; insecticides for agricultural and horticultural use containing the same as the active ingredient; and usage thereof: (1) [wherein A is optionally substitute...
|
|
WO/2004/018410A1 |
A novel agricultural chemical, especially an insecticide or acaricide; and a substituted benzanilide compound represented by the general formula (1): (1) G-7 G-13 G-71 [wherein G represents a ring represented by G-7, G-13, G-71, etc.; W1...
|
|
WO/2004/018414A2 |
The present invention relates to compounds of formula I or a pharmaceutically acceptable salt thereof, wherein X=NH Y=CO, CS, -C(=N-CN) or X and Y together form an alkene, or C3-C5 cycloalkyl; R1 is -COOH; R2 is an electron withdrawing g...
|
|
WO2003006425A9 |
The present invention relates to compounds of the general formula (I); or salts thereof, as anti-inflammatory, immunomodulatory and anti-proliferatory agents.
|
|
WO/2004/016221A2 |
Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides sulfonami...
|
|
WO/2004/014844A2 |
This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as antagonists,...
|
|
WO/2004/014825A1 |
The invention relates to compounds of the formula, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; which exhibit anti-inflammatory and immunodulatory activity. Also di...
|
|
WO2003027234A9 |
The present invention makes available methods and reagents for modulating proliferation or differentiation in a cell or tissue comprising contacting the cell with a hedgehog agonist, such as the compounds depicted in Figures 32 and 33. I...
|
|
WO/2004/014847A1 |
The present invention relates to sulfones that are useful in the treatment of chemokine-mediated disorders. In certain embodiments, the present invention concerns the compounds that are MCP-1 receptor antagonists.
|
|
WO/2004/014846A1 |
The present invention relates to modafinil polymorphic forms, methods of preparation thereof, pharmaceutical compositions and methods of therapeutic treatment involving modafinil polymorphic forms.
|
|
WO/2004/014424A1 |
Activated polymeric bicine derivatives such asas well as conjugates made therewith are disclosed. Methods of making and using the bicine derivatives are also disclosed
|
